Sugi Predict

Sugi Predict / Compounds / SCHEMBL2662697

SCHEMBL2662697

SCHEMBL2662697

Cc1nnnn1-c1ccc(/C(=C\C2CCCC2)C(=O)Nc2nccs2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 5/20 0.50
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TSHR P16473 3/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ HSD17B10 Q99714 3/20 0.37
▸ GAA P10253 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ HTT P42858 3/20 0.37
▸ USP2 O75604 2/20 0.37
▸ LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396801 1.00 GCK (0.50) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2651446 0.83 GCK (0.48) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2658259 0.83 GCK (0.48) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2651442 0.83 GCK (0.48) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2658257 0.83 GCK (0.48) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2663853 0.82 GCK (0.47) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2658164 0.82 GCK (0.47) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6174666 0.82 GCK (0.47) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2658171 0.82 GCK (0.47) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5381699 0.81 ADRA1A (0.36) KMT2AALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1594863-A1 TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS Prosidion Limited (GB) 2005-11-16 — — EP claimed
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds OSI PHARMACEUTICALS, INC. 2004-09-23 — — US claimed
WO-2004072066-A1 TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS PROSIDION LIMITED (GB) 2004-08-26 — — WO claimed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 — — US disclosed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 — — US disclosed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 — — US disclosed
WO-2004072066-A1 TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS PROSIDION LIMITED (GB) 2004-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds GCKR, GCK, GALK1 GCK 2/4885MEN1 4067/4885KMT2A 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.